ERBB2 and triple-negative breast carcinoma: For example, HER2-positive patients can be treated with monoclonal antibodies such as trastuzumab or pertuzumab, whereas triple-negative breast cancer BMs treatment relies on BBB-permeable chemotherapeutics, such as capecitabine, cisplatin, and temozolomide [285,286].